The following Listing of the Claims will replace all prior versions and all prior listings:

Listing of The Claims:

1. (Currently amended) A method for treating a solid cancerous tumor, which comprises administering to a mammal in need of such treatment an effective amount of DMXAA or a pharmaceutically acceptable salt or ester thereof and administering an effective amount of gemcitabine ~~at least one of a compound selected from platinum compounds, vinca alkaloids, cyclophosphamide, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors~~.

2. (Currently amended) A method for treating a solid cancerous tumor, which comprises administering to a mammal in need of such treatment an effective amount of DMXAA or a pharmaceutically acceptable salt or ester thereof and administering an effective amount of gemcitabine ~~at least one of a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, wherein the DMXAA or pharmaceutically acceptable salt or ester thereof and the at least one of a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors are administered~~ in a potentiating ratio.

3. (Currently amended) ~~A~~ The method according to claim 1 or claim 2, wherein the DMXAA or pharmaceutically acceptable salt or ester thereof and the gemcitabine ~~the at least one of a compound selected from platinum compounds, vinca alkaloids, cyclophosphamide, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors~~ are administered concomitantly.

4. (Currently amended) A method for treating a solid cancerous tumor, which comprises administering to a mammal in need of such treatment an effective amount of DMXAA or a pharmaceutically acceptable salt or ester thereof and administering an effective amount of gemcitabine ~~at least one of a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors~~, wherein the DMXAA or pharmaceutically acceptable salt or ester thereof and the gemcitabine ~~at least one of a compound selected from~~

~~platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors~~ are administered sequentially.

5. (Cancel)

6. (Cancel)

7. (Currently amended) A composition comprising a combination of DMXAA or a pharmaceutically acceptable salt or ester thereof and gemcitabine ~~at least one of a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors~~.

8. (Currently amended) ~~A~~ The composition according to claim 7 wherein the DMXAA or a pharmaceutically acceptable salt or ester thereof and the gemcitabine ~~the at least one of a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors~~ are present in a potentiating ratio.

9. (Cancel)

10. (Cancel)

11. (Currently amended) A pharmaceutical formulation comprising a combination of DMXAA or a pharmaceutically acceptable salt or ester thereof and gemcitabine ~~at least one of a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors~~ in association with one or more pharmaceutically acceptable carriers therefor.

12. (Original) A pharmaceutical formulation according to claim 11 wherein the formulation is adapted for intravenous administration.

13. (Currently amended) ~~A~~ The pharmaceutical formulation according to claim 11 or 12 wherein the DMXAA or pharmaceutically acceptable salt or ester thereof and the gemcitabine ~~the at least one of a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors~~ are present in a potentiating ratio.

14. (Cancel)

15. (Cancel)

16. (Currently amended) A process for the preparation of a pharmaceutical formulation which process comprises bringing into association a combination of DMXAA or a pharmaceutically acceptable salt or ester thereof and gemcitabine ~~at least one of a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors~~ with one or more pharmaceutically acceptable carriers therefor.

17. (Currently amended) ~~A~~ The process according to claim 16 wherein the DMXAA or pharmaceutically acceptable salt or ester thereof and the gemcitabine ~~the at least one of a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors~~ are present in a potentiating ratio.

18. (cancel)

19. (cancel)

20. (Currently amended) A kit comprising in association for separate administration DMXAA or a pharmaceutically acceptable salt or ester thereof and gemcitabine ~~at least one of a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors~~.

21. (Currently amended) ~~A~~ The kit according to claim 20 wherein the DMXAA or pharmaceutically acceptable salt or ester thereof and gemcitabine ~~the at least one of a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors~~ are present in a potentiating ratio.

22. (Cancel)

23. (Cancel)

24. (Cancel)

25. (Cancel)

26. (Cancel)

27. (Cancel)